SCL Science

SCL Science Stock-Based Compensation

The Stock-Based Compensation (SBC) of SCL Science (246960.KQ) as of Nov 18, 2026 is -43.10 M KRW. In the previous year, Stock-Based Compensation (SBC) was 25.96 M KRW — a change of -266.00% (lower).

Stock-Based Compensation

-43.10 MKRW

YoY

-266.00%

Last updated:

Stock-Based Compensation (SBC) of SCL Science is 2025 -43.10 M KRW. Stock-Based Compensation (SBC) of SCL Science was 2024 25.96 M KRW. It decreases by -266.00% lower compared to the previous year.

The SCL Science Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
10.64 M KRW
Jan 1, 2020
37.30 M KRW
Jan 1, 2021
31.96 M KRW
Jan 1, 2022
129.12 M KRW
Jan 1, 2023
75.91 M KRW
Jan 1, 2024
25.96 M KRW
Jan 1, 2025
-43.10 M KRW
The SCL Science Stock-Based Compensation history
YEARStock-Based CompensationYoY
-43.10 MKRW-266.00%
25.96 MKRW-65.80%
75.91 MKRW-41.21%
129.12 MKRW+304.02%
31.96 MKRW-14.32%
37.30 MKRW+250.47%
10.64 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Stock-Based Compensation (SBC) of SCL Science is -43.10 M KRW in 2025.

Stock-Based Compensation (SBC) of SCL Science changed from 25.96 M KRW to -43.10 M KRW, representing a -266.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) SCL Science since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s SCL Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SCL Science

All Key Metrics — SCL Science